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Background: To examine whether ovarian puncture for immature oocyte retrieval and in-vitro maturation (IVM) has
an effect on the endocrine profile of patients with polycystic ovary syndrome (PCOS).
Methods: Twenty-two consecutive patients with PCOS undergoing IVM treatment were included. Serum anti-
Müllerian hormone (AMH), sex hormone-binding globulin (SHBG), total testosterone (TT) and luteinized hormone (LH)
levels were analyzed at the start of the cycle, on the day of immature oocyte retrieval (OR) and at fixed intervals
thereafter, for up to three months after OR.
Results: Five days after OR circulating AMH, TT, calculated free testosterone (FTc), and LH levels were significantly
reduced and circulating SHBG was significantly increased. Two weeks after OR, TT, FTc and LH remained reduced,
whereas circulating AMH and SHBG levels recovered to pre-puncture values. Three months after OR, all circulating
hormone levels had recovered to baseline values.
Conclusion: Ovarian puncture for the retrieval of immature oocytes and IVM in patients with PCOS has a significant
impact on the ovarian endocrine profile, but this impact is brief and transient.
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Total testosteroneBackground
In-vitro maturation (IVM) of oocytes is a mild-approach
assisted reproductive technology (ART) whereby imma-
ture oocytes are retrieved from small antral follicles. Al-
though life birth rates after IVM are still lower than
after conventional hormone-driven methods of ART that
encompass oocyte maturation in vivo, IVM has promis-
ing potential in patients who suffer from significant hor-
monal side effects and an increased risk of ovarian
hyperstimulation syndrome (OHSS) if they undergo con-
ventional ART. Different promising strategies have been
used to reduce the risk of OHSS in patients with poly-
cystic ovary syndrome (PCOS) including ovarian stimu-
lation using a GnRH-antagonist protocol followed by a
GnRH-agonist ovulation trigger [1], low-dose stimula-
tion protocol using highly purified follicle-stimulation* Correspondence: cortegah@gmail.com
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article, unless otherwise stated.hormone [2] and treatment segmentation with elective
freezing of all oocytes or embryos [3]. Although these
strategies can reduce OHSS incidence significantly, they
do not completely eliminate the occurrence of OHSS in
high-risk patients [4]; in these patients, IVM is a poten-
tial viable method to prevent OHSS [5]. Therefore, IVM
could be highly suitable for patients with polycystic
ovary syndrome.
During an IVM cycle, egg collection is typically per-
formed using multiple transvaginal punctures of un-
stimulated or minimally stimulated ovaries; a recent
retrospective study suggested that this egg collection
procedure may exhibit a similar effect to that of laparo-
scopic ovarian drilling (LOD) [6]. According to this trial,
oocyte retrieval for IVM was associated with an in-
creased number of mature oocytes and embryos in sub-
sequent in vitro fertilisation (IVF) cycles, implying that
these punctures may have improved the endocrinological
profile of patients with polycystic ovaries. Laparoscopic
ovarian drilling (LOD) is widely used to induce ovulationCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with clomiphene citrate (CC), although there is no evi-
dence for a significant difference in rates of clinical preg-
nancy, live birth, or miscarriage in women with CC
resistant PCOS undergoing LOD as compared to other
medical treatments [7]. Nonetheless, in spite of the hy-
pothesis that ovarian puncture of polycystic ovaries may
have a drilling-like effect, no prospective study has eval-
uated the effect of ovarian puncture for immature oocyte
retrieval and IVM on the endocrine profile in patients
with PCOS. Therefore, we performed a prospective co-
hort study to examine the alteration of serum anti-
Müllerian hormone (AMH) and other hormone levels in
relation to the oocyte retrieval procedure in a consecu-




From January 2012 to July 2012, serial serum levels of
endocrine parameters from 22 consecutive patients with
PCOS undergoing non-hCG-triggered oocyte retrieval
for IVM (IVM-OR) were prospectively analyzed. The in-
clusion criteria for study were as follows: women youn-
ger than 35 years old, diagnosed with PCOS undergoing
IVM cycle. Patients were classified as having PCOS if
they fulfilled the Rotterdam criteria for PCOS [8,9].
Patients with congenital adrenal hyperplasia, Cushing’s
syndrome and androgenic-secreting tumors were ex-
cluded. Male factor infertility was not an exclusion cri-
terion. Written informed consent was obtained from all
patients before inclusion in the trial. The study was ap-
proved by local Ethical Committee.
IVM cycle characteristics
In oligomenorrhoeic and amenorrhoeic patients, a with-
drawal bleeding was induced using oral dydrogesterone
(Duphaston®, Abott Products GmbH, Hannover, Germany;
10 mg daily for 5 days). All patients received transdermal
17ß-estradiol gel (Oestrogel®, Besins Healthcare, Paris,
France) for endometrial preparation, at a starting dose of
4 mg daily for seven consecutive days, after which the
dose was increased to 7.5 mg daily. After a mean interval
of 10.7 ± 2.6 days of 17ß-estradiol gel administration all
patients received 150 IU highly purified human meno-
pausal gonadotropin (HP-hMG) (Menopur®; Ferring
Pharmaceuticals A/S, Copenhagen, Denmark) daily for
three consecutive days. Transvaginal oocyte retrieval
was scheduled 42 hours after the last injection of HP-
hMG and was performed using a single lumen 17 GA nee-
dle (Cook Medical, K-OPS-1230-VUB, Limerick, Ireland)
at an aspiration pressure of 70 mm Hg. To avoid the re-
trieval of oocytes at divergent stages of maturation at the
time of retrieval, no human chorionic gonadotropin(hCG) trigger was administered. Cumulus-oocyte com-
plexes (COCs) were matured for 40 hours in MediCult
IVM® System (Origio, Måløv, Denmark). Intracytoplasmic
sperm injection (ICSI) and embryo transfer were per-
formed as previously described [10,11].
Measurements and follow-up
Serial blood sampling for the analysis of serum levels of
AMH, total testosterone (TT), calculated free testoster-
one (FTc), sex hormone-binding globulin (SHBG), fol-
licle stimulating hormone (FSH) and luteinized hormone
(LH) was performed on day two of the IVM treatment
cycle, on the day of IVM-OR (before the oocyte collec-
tion), five days after IVM-OR and two weeks after IVM-
OR.
To extend the interval of follow-up after the IVM
cycle, patients were invited to return to the clinic for
further blood sampling three months after oocyte re-
trieval and a subanalysis was performed in those who
did return.
Assays
Serum AMH levels were measured with the Beckman
Coulter Gen II ELISA kit (Beckman Coulter, Marseille,
France). To circumvent inter-assay variability, all samples
were processed simultaneously. Serum FSH, LH, estradiol
(E2), progesterone, SHBG and total testosterone levels
were measured on a Cobas 6000 immunoanalyser (Roche
Diagnostics, Mannheim, Germany). Free testosterone was
calculated from total serum testosterone and SHBG as
measured by immunoassay and assuming a fixed albumin
concentration as described previously [12].
Statistical analysis
Data were analyzed using SPSS 20.0 statistical software.
Normality of the distribution for each of the outcomes
was examined using the Shapiro-Wilk test. Due to the lack
of normality in the distribution, paired analysis was per-
formed using the Wilcoxon Signed-Rank Test. Differences
were considered statistically significant when P ≤ 0.05.
Results
Table 1 shows baseline patient and hormonal character-
istics of the study population.
Circulating hormone levels during the IVM cycle
On day two of the cycle (cd2), the mean basal levels of
serum AMH, E2, TT, FTc and SHBG were 8.9 ± 4.0 μg/L,
47.4 ± 13.1 ng/L, 0.36 ± 0.13 nmol/L, 5.0 ± 3.6 pmol/L and
74.6 ± 59.1 nmol/L, respectively. After endometrial prim-
ing with transdermal 17ß-estradiol and a cumulative dose
of 450 IU HP-hMG, a second blood sample was obtained
on the day of IVM-OR: serum AMH levels were signifi-
cantly reduced to 7.5 ± 3.2 μg/L (p = 0.005) and serum E2
Table 1 Baseline patient characteristics
Mean ± SD
Age (y) 29.7 ± 3.5
BMI (kg/m2) 30.3 ± 9.0
AFC 20.2 ± 11.0
FSH (IU/L) 5.5 ± 1.2
E2 (ng/L) 47.3 ± 13.1
LH (IU/L) 7.9 ± 4.4
Progesterone (μg/L) 0.6 ± 0.2
BMI body mass index, AFC antral follicle count, FSH follicle stimulating
hormone, E2 Estradiol, LH Luteinizing hormone.
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1831 ng/L (p < 0.001), 0.48 ± 0.21 nmol/L (p = 0.002, resp).
FTc, SHBG and LH levels all remained unchanged on the
day of OR compared to basal cd2 values [5.3 ± 2.9 pmol/L
(p = 0.570), 85.1 ± 48.3 nmol/L (p = 0.082) and 10.2 ±
7.8 IU/L, p = 0.277, resp.].
Five days after IVM-OR, circulating AMH levels sig-
nificantly dropped to 6.3 ± 3.2 μg/L (p = 0.001) compared
to values at IVM-OR and circulating levels of TT, FTc
and LH levels were also significantly reduced [0.28 ±
0.12 nmol/L (p < 0.001), 2.9 ± 1.8 pmol/L (p < 0.001) and
5.8 ± 4.1 IU/L (p = 0.023), resp.]. Circulating SHBG was
significantly increased to 99.4 ± 57.3 nmol/L (p = 0.017).
These significant changes of circulating AMH and SHBG
levels were no longer observed two weeks after OR: circu-
lating AMH recovered to 7.6 ± 3.6 μg/L (p = 0.910) and
SHBG recovered to 81.6 ± 54.4 nmol/L (p = 0.875). How-
ever, TT, FTc and LH remained significantly reduced
two weeks after IVM-OR, compared to levels at IVM-OR
[0.22 ± 0.1 nmol/L (p = 0.001), 2.7 ± 1.5 pmol/L (p = 0.002)
and 3.7 ± 3.0 IU/L (p = 0.008), resp.] (Table 2).
Because of the significant impact of IVM-OR on
serum androgens and LH levels two weeks after IVM-
OR, patients were invited to have further blood sampling
for hormone analysis three months after IVM-OR.
Circulating hormone levels three months after IVM-OR
Blood samples for hormone analysis were obtained from
five patients at three months’ follow-up. The remainingTable 2 Endocrine profile after oocyte retrieval (OR) for IVM i
Basal OR day
(All values compared to basal values)
5 da
(All v
AMH (μg/L) 8.9 ± 4.0 7.5 ± 3.2* 6.3 ±
TT (nmol/L) 0.36 ± 0.13 0.48 ± 0.21* 0.28
FTc (pmol/L) 5.0 ± 3.6 5.3 ± 2.9NS 2.9 ±
SHBG (nmol/L) 74.6 ± 59.1 85.1 ± 48.3NS 99.4
LH (IU/L) 7.9 ± 4.4 10.2 ± 7.8NS 5.8 ±
Values represent mean and SD.
AMH Antimüllerian hormone, TT total testosterone, SHBG sex hormone-binding glob
FSH Follicle-stimulating hormone. *P < 0.05; **P < 0.001; NS not statistically different17 patients were unavailable for this subanalysis: 10 pa-
tients had undergone a second IVM-OR procedure in
the meantime, 2 patients were receiving hormonal treat-
ment, 3 patients had become pregnant after the IVM
treatment cycle and 2 patients were lost to follow-up.
Three months after IVM-OR, no significant differences
were found when comparing circulating levels of AMH,
TT, FTc, SHBG and LH to basal levels (a) or OR levels (b).
Total testosterone, FTc and LH levels had recovered to
0.37 ± 0.16 nmol/L (p = 0.225(a), p = 0.5(b)), 4.0 ± 2.4 pmol/L
(p = 0.893 (a), p = 0.893 (b)) and 5.8 ± 4.7 IU/L (p = 0.345 (a),
p = 0.686 (b)), respectively (Table 2).
Discussion
To our knowledge, this is the first prospective study to
examine the effect of ovarian puncture for retrieval of
immature oocytes on the endocrine profile in patients
with PCOS undergoing IVM treatment. The results of
our study suggest that the effect of oocyte retrieval of
immature oocytes on the endocrine profile of these pa-
tients is significant but transient and that ovarian punc-
ture for IVM does not offer long-term prospects of an
alteration of the endocrine profile in patients with PCOS,
as observed after LOD. Although the exact mechanism of
action of LOD is unknown, it is likely that multiple ovarian
punctures may destroy ovarian androgen-producing tissue
and by doing so result in reduced peripheral conversion of
androgen into oestrogen [13]. This is further documented
by the observation that LOD can restore ovulation, results
in good pregnancy rates [14,15] and significantly reduces
AMH levels [16], LH/FSH ratio, serum concentration of
LH, testosterone and free androgen index. The effect of
LOD on these endocrine parameters often persists for
many years after the procedure [17].
Although gonadotropin doses in IVM cycles are typic-
ally much lower than those administered in conventional
ART (c-ART) cycles, clinical protocols for IVM often in-
clude mild stimulation using low-dose gonadotropins
and/or oral or transdermal estrogens [18-20] to increase
endometrial thickness. In our study, patients received
14.7 ± 2.5 days of transdermal oestradiol and 450 IU HP-
hMG cumulatively for endometrial priming beforen PCOS
ys after OR
alues compared to OR values)
2 weeks after OR
(All values compared to OR values)
3.2* 7.6 ± 3.6NS
± 0.12** 0.22 ± 0.1*
1.8** 2.7 ± 1.5*
± 57.3* 81.6 ± 54.4NS
4.1* 3.7 ± 3.0*
ulin, FTc calculated free testosterone, LH Luteinizing hormone,
.
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(1,098 ± 1,831 ng/L) on the day of OR-IVM. The obser-
vation that serum AMH levels were significantly reduced
on the day of IVM-OR (p = 0.005) is in accordance with
previous studies showing reduced AMH levels after con-
trolled ovarian stimulation for c-ART [21,22]. Neverthe-
less, although in c-ART cycles the number of small
antral follicles producing AMH decreases as follicles
progressively grow in response to FSH stimulation, this
mechanism does not occur in IVM-cycles: in the study
presented here, IVM-OR was performed when follicles
had a maximal mean diameter of 10 mm. Because previ-
ous studies have shown that FSH increases estradiol
levels and suppresses AMH secretion [23,24], we
propose that the observed significant reduction of circu-
lating AMH levels on the day of IVM-OR is caused by
increased serum estradiol levels secondary to exogenous
administration of estradiol and gonadotropins. Elevated
estradiol levels also enhance hepatic SHBG synthesis
and secretion, resulting in increased SHBG levels on the
day of IVM-OR. TT values were also increased after
mild ovarian stimulation for IVM (p = 0.002). This might
be explained by the fact that the amounts of LH and
hCG present in HP-hMG formulations are capable of
stimulating androgen substrate production from theca
cells [25].
Taking into account that decreased AMH biosynthesis
following LOD restores ovulatory function through en-
hanced follicular sensitivity to circulating FSH levels, we
speculated that a similar effect might occur following
immature oocyte retrieval from small follicles. LOD has
been proven to significantly reduce circulating AMH
levels [26], with values remaining significantly reduced
up to 6 months after the procedure [16]. The mechanic
effect of LOD on polycystic ovaries may reside in de-
struction of small antral and pre-antral follicles, besides
stroma, resulting in a relatively long term impact on cir-
culating levels of AMH, LH, and total and free testoster-
one [27]. As a result of these changes, increased
ovulation and pregnancy rates have been documented
after LOD in patients with PCOS. Transvaginal aspir-
ation of small antral follicles has been proposed as a
method to induce ovulation in anovulatory patients with
PCO [28]: in a series of 18 patients, Mio et al. demon-
strated a mean ovulation rate of 52.6% in subsequent cy-
cles after multiple antral follicular punctures. Using a
similar approach, Ferraretti et al. performed transvaginal
ovarian puncture in PCOS patients to improve IVF re-
sults and named this procedure “transvaginal ovarian
drilling” [29]. In a case-control study in 42 patients with
PCOS who had IVM treatment before conventional IVF
and 48 patients with PCOS who had not had IVM be-
fore, significantly more oocytes and embryos in subse-
quent IVF cycles were obtained in patients who had hadIVM treatment [6]. Moreover, Frantz et al. reported
three spontaneous pregnancies in women with PCOS
after transvaginal ovarian punctures for IVM. Although
this is small case report series the authors concluded
that multiple ovarian punctures for IVM in PCOS pa-
tients may have contributed to their pregnancy in the
months following the IVM procedure [30]. However, al-
though the above observations imply that multiple punc-
tures for IVM may have an effect similar to that of LOD,
no study has been conducted to provide a biological ex-
planation for this effect. In the current study we exam-
ined the true impact of transvaginal puncture of
minimally stimulated polycystic ovaries on the endocrine
profile and conclude that the effect is only temporary:
serum AMH concentrations had returned to levels be-
fore oocyte retrieval within two weeks after IVM-OR
and the reduction of androgen levels had disappeared
within three months after IVM-OR, at least in the subset
of patients who had a follow-up at three months. This
rather short-term effect compared to LOD might be ex-
plained by the relatively less invasive nature of ovarian
puncture for the retrieval of immature oocytes, probably
because of the absence of thermal energy. Hence, the
new wave of developing small antral follicles that is ob-
served as early as five days after IVM-OR [31] will result
in restored steroidogenesis and AMH synthesis soon
after the procedure.
In spite of its prospective design, the current study has
several limitations. First, serial hormone analysis was re-
stricted to the IVM cycle itself and only a small subset
of patients were available for hormone profiling at three
months’ follow-up. After one IVM cycle, the majority of
patients in this study were not pregnant and proceeded
with reproductive treatment shortly after this failed
treatment cycle. The observation, at least in the small
subset of five patients available for follow-up, that the
endocrine profile was unchanged at three months’
follow-up, leads us to suggest that it is highly unlikely
that the results would have been different at longer in-
tervals. However, follow-up data were only available for
five patients, which significantly limits the ability to
generalize these results to a larger population.
Secondly, this study only focused on markers of the
endocrine profile; the effect of ovarian puncture on ovu-
latory function and clinical outcomes following IVM-OR
could not be investigated within the scope of this study,
since the majority of patients decided to have further
ART cycles shortly after the study cycle, rather than
await potential effects of treatment on endocrine or ovu-
latory function.
Furthermore, the effect of multiple ovarian punctures
for IVM on the endocrine profile described in this study
has not been compared to the effect of a regular oocyte
retrieval in women with PCOS undergoing a c-ART. A
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firm the findings of the current study.
Our study cohort consisted of patients with PCOS,
who were generally overweight or obese (mean BMI
30.3 ± 9.0 kg/m2) but who had relatively low serum
levels of LH levels (7.9 ± 4.4 IU/L) and normal markers
of hyperandrogenism (TT 0.36 ± 0.13 nmol/L, FTc 5.0 ±
3.6 pmol/L and SHBG 74.6 ± 59.1 nmol/L). In a study
investigating parameters that are predictive of ovulation
rates and pregnancy in 200 patients with PCOS who
underwent LOD, it was shown that morbid obesity and
high levels of androgens, among other parameters, are
associated with low chances of response to LOD [32].
According to these findings, the patients in our study
would be predicted good responders to LOD in terms of
ovulatory function and clinical outcomes. Again, long-
term follow-up to evaluate the effect of oocyte retrieval
for IVM on ovulation rates and pregnancy could not be
performed in our patients.Conclusions
The clinical implication from the current study is that
ovarian puncture for immature oocyte retrieval appears
not to have a long-term effect on the endocrine profile
in patients with PCOS, contrary to what is observed
after LOD. The effect of ovarian puncture appears to be
transient and completely recovers three months after oo-
cyte retrieval.
The lower efficiency of IVM systems compared to
gonadotropin-driven ART precludes the widespread use of
current IVM protocols. Improvement of IVM culture
media could substantially enhance the potential of this
technology [33], especially in patients with PCOS, in whom
conventional methods of ART can be cumbersome and are
associated with an increased risk of OHSS. Whether ovar-
ian puncture for IVM treatment could enhance clinical
outcomes of subsequent conventional ART treatment in
patients with PCOS, remains to be confirmed. The short-
term improvement of endocrine parameters related to ex-
cess follicle number and increased androgen biosynthesis
in patients with PCOS might result in an increased number
of oocytes and embryos in IVF cycles following IVM as ob-
served by Agdi et al. [6]. However, the data from our study
do not confirm this hypothesis.Competing interests
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